Ablysinol is one of 31 small molecule programs targeting Pancreatic Cancer. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
1063 competitors in Pancreatic Cancer
Ablysinol
Gemzar
MS Contin
Medrol
Byetta
Active Comparator
Secretin-Ferring
Concurrent Lenvatinib
Rybelsus
Gemcitabine/nab-Paclitaxel
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Regulatory
Jun 21, 2018
ABLYSINOL
NDA NDA207987
Oct 23, 2025
DEHYDRATED ALCOHOL
NDA NDA214988
Sources
Details